740 research outputs found
A morphometric study of nucleolar organiser regions in cervical intraepithelial neoplasia
The study sought a correlation between the number of AgNOR granules and
the degree of cervical intraepithelial neoplasia (CIN). Thirty-five sections (5 normal,
10 CIN1, 10 CIN2 and 10 CIN3) were subjected to retrospective analysis.
The percentage of cells with 1, 2, 3, 4 and more AgNORs was calculated and the
number of granules per 100 cells was counted. The number of cells containing
single granules decreases. However, the number increases with CIN level when
the cells contain 4 and more AgNORs. The number of granules per 100 cells also
increases with the degree of CIN. It can be thus concluded that the number of cells
with 4 and more AgNOR granules can serve as a CIN differentiation exponent
The influence of doxycycline on articular cartilage in experimental osteoarthrosis induced by iodoacetate
The experiment was performed on 36 Wistar rats. On the first day of the experiment
iodoacetate was administered to the left posterior knee joint of the 18 rats
which composed Group I. The second group of 18 rats received additionally
doxycycline (doxy) through the gastric tube in doses comparable with those of
doxycycline used in humans. The experiment lasted 21 days. The animals were
sacrificed after 7, 14 and 21 days in groups of 6 rats each. In sections stained
with Safranin 0 semiquantitative histochemical intensity tests were performed
on articular cartilage glycosaminoglycans (GAG) using a four-point scale (0–3).
In the first group examined destructive lesions in the articular cartilage and weak
reactivity on GAG were noted at all stages of the experiment. The intensity of
GAG staining was higher in the second group after 14 and especially after 21 days,
which may suggest a protective action of doxy on articular cartilage
Expression of the apoptotic markers in normal breast epithelium, benign mammary dysplasia and in breast cancer
Apoptosis and proliferation are processes associated with the development and
progression of breast cancer. The sensitivity of tumour cells to the induction of
apoptosis depends on the balance between pro- and anti-apoptotic proteins.
The expression of Bak and Bcl-2 was examined using an immunohistochemical
method in 71 primary breast cancers. Furthermore, Bcl-2 and Bak were assessed
in the normal mammary gland as well as in benign mammary dysplasia adjacent
to breast cancer. Positive immunostaining for Bcl-2 was observed in 77.8% of
cases of normal breast epithelium (NBE), 93% of benign dysplasia without intraductal
proliferation (BBD) as well as in 94% of intraductal proliferative lesions of
the breast (BIPL). Expression of Bak was detected in 39% of cases of NBE, 45%
of BBD and in 67% of BIPL. In breast cancer Bcl-2 and Bak expression was found
in 83% and 70% of the cases studied, respectively. Increased Bcl-2 expression in
primary tumours significantly correlated with favourable prognostic factors, namely
pT1, G2 and lack of metastases to the regional lymph nodes (p < 0.01,
p < 0.03, p < 0.02, respectively). There were no relationships between Bak and
the clinicopathological features studied, but our results indicate changes in the
expression of Bak during breast cancer development and progression. It would
appear to be important to assess and compare pro- and anti-apoptotic proteins
between normal mammary gland, benign mammary dysplasia and the primary
tumours of breast cancer. This knowledge should be helpful in understanding
breast cancer development and progression
Hepatic profile analyses of tipranavir in Phase II and III clinical trials
<p>Abstract</p> <p>Background</p> <p>The risk and course of serum transaminase elevations (TEs) and clinical hepatic serious adverse event (SAE) development in ritonavir-boosted tipranavir (TPV/r) 500/200 mg BID recipients, who also received additional combination antiretroviral treatment agents in clinical trials (TPV/r-based cART), was determined.</p> <p>Methods</p> <p>Aggregated transaminase and hepatic SAE data through 96 weeks of TPV/r-based cART from five Phase IIb/III trials were analyzed. Patients were categorized by the presence or absence of underlying liver disease (+LD or -LD). Kaplan-Meier (K-M) probability estimates for time-to-first US National Institutes of Health, Division of AIDS (DAIDS) Grade 3/4 TE and clinical hepatic SAE were determined and clinical actions/outcomes evaluated. Risk factors for DAIDS Grade 3/4 TE were identified through multivariate Cox regression statistical modeling.</p> <p>Results</p> <p>Grade 3/4 TEs occurred in 144/1299 (11.1%) patients; 123/144 (85%) of these were asymptomatic; 84% of these patients only temporarily interrupted treatment or continued, with transaminase levels returning to Grade ≤ 2. At 96 weeks of study treatment, the incidence of Grade 3/4 TEs was higher among the +LD (16.8%) than among the -LD (10.1%) patients. K-M analysis revealed an incremental risk for developing DAIDS Grade 3/4 TEs; risk was greatest through 24 weeks (6.1%), and decreasing thereafter (>24-48 weeks: 3.4%, >48 weeks-72 weeks: 2.0%, >72-96 weeks: 2.2%), and higher in +LD than -LD patients at each 24-week interval. Treatment with TPV/r, co-infection with hepatitis B and/or C, DAIDS grade >1 TE and CD4<sup>+ </sup>> 200 cells/mm<sup>3 </sup>at baseline were found to be independent risk factors for development of DAIDS Grade 3/4 TE; the hazard ratios (HR) were 2.8, 2.0, 2.1 and 1.5, respectively. Four of the 144 (2.7%) patients with Grade 3/4 TEs developed hepatic SAEs; overall, 14/1299 (1.1%) patients had hepatic SAEs including six with hepatic failure (0.5%). The K-M risk of developing hepatic SAEs through 96 weeks was 1.4%; highest risk was observed during the first 24 weeks and decreased thereafter; the risk was similar between +LD and -LD patients for the first 24 weeks (0.6% and 0.5%, respectively) and was higher for +LD patients, thereafter.</p> <p>Conclusion</p> <p>Through 96 weeks of TPV/r-based cART, DAIDS Grade 3/4 TEs and hepatic SAEs occurred in approximately 11% and 1% of TPV/r patients, respectively; most (84%) had no significant clinical implications and were managed without permanent treatment discontinuation. Among the 14 patients with hepatic SAE, 6 experienced hepatic failure (0.5%); these patients had profound immunosuppression and the rate appears higher among hepatitis co-infected patients. The overall probability of experiencing a hepatic SAE in this patient cohort was 1.4% through 96 weeks of treatment. Independent risk factors for DAIDS Grade 3/4 TEs include TPV/r treatment, co-infection with hepatitis B and/or C, DAIDS grade >1 TE and CD4<sup>+ </sup>> 200 cells/mm<sup>3 </sup>at baseline.</p> <p>Trial registration</p> <p>US-NIH Trial registration number: NCT00144170</p
Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli
PURPOSE: Recent in vitro studies suggested that the autocrine leptin loop might contribute to breast cancer development by enhancing cell growth and survival. To evaluate whether the leptin system could become a target in breast cancer therapy, we examined the expression of leptin and its receptor (ObR) in primary and metastatic breast cancer and noncancer mammary epithelium. We also studied whether the expression of leptin/ObR in breast cancer can be induced by obesity-related stimuli, such as elevated levels of insulin, insulin-like growth factor-I (IGF-I), estradiol, or hypoxic conditions.
EXPERIMENTAL DESIGN: The expression of leptin and ObR was examined by immunohistochemistry in 148 primary breast cancers and 66 breast cancer metastases as well as in 90 benign mammary lesions. The effects of insulin, IGF-I, estradiol, and hypoxia on leptin and ObR mRNA expression were assessed by reverse transcription-PCR in MCF-7 and MDA-MB-231 breast cancer cell lines.
RESULTS: Leptin and ObR were significantly overexpressed in primary and metastatic breast cancer relative to noncancer tissues. In primary tumors, leptin positively correlated with ObR, and both biomarkers were most abundant in G3 tumors. The expression of leptin mRNA was enhanced by insulin and hypoxia in MCF-7 and MDA-MB-231 cells, whereas IGF-I and estradiol stimulated leptin mRNA only in MCF-7 cells. ObR mRNA was induced by insulin, IGF-I, and estradiol in MCF-7 cells and by insulin and hypoxia in MDA-MB-231 cells.
CONCLUSIONS: Leptin and ObR are overexpressed in breast cancer, possibly due to hypoxia and/or overexposure of cells to insulin, IGF-I, and/or estradiol
Efficacy of Direct-Acting Antiviral Combination for Patients with Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease
© 2016 AGA Institute. Background & Aims Although hepatitis C virus (HCV) infection is common in patients with end-stage renal disease, highly efficacious, well-tolerated, direct-acting antiviral regimens have not been extensively studied in this population. We investigated the safety and efficacy of ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir (with or without ribavirin) in a prospective study of patients with stage 4 or 5 chronic kidney disease (CKD). Methods We performed a single-arm, multicenter study of treatment-naïve adults with HCV genotype 1 infection, without cirrhosis and with CKD stage 4 (estimated glomerular filtration rate, 15-30 mL/min/1.73 m2) or stage 5 (estimated glomerular filtration rate, /min/1.73 m2or requiring hemodialysis). Twenty patients were given ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir for 12 weeks. Patients with HCV genotype 1a infections also received ribavirin (n = 13), whereas those with genotype 1b infection did not (n = 7). The primary end point was sustained virologic response (serum HCV RNA /mL) 12 weeks after treatment ended (SVR12). We collected data on on-treatment adverse events (AEs), serious AEs, and laboratory abnormalities. Results All 20 patients completed 12 weeks of treatment. Eighteen of the 20 patients achieved SVR12 (90%; 95% confidence interval: 69.9-97.2). One patient death after the end of the treatment (unrelated to the treatment) and 1 relapse accounted for the 2 non-SVRs. Adverse events were primarily mild or moderate, and no patient discontinued treatment due to an AE. Four patients experienced serious AEs; all were considered unrelated to treatment. Ribavirin therapy was interrupted in 9 patients due to anemia; 4 received erythropoietin. No blood transfusions were performed. Conclusions In a clinical trial, the combination of ombitasvir, paritaprevir, and ritonavir, administered with dasabuvir, led to an SVR12 in 90% of patients with HCV genotype 1 infection and stage 4 or 5 CKD. The regimen is well tolerated, though RBV use may require a reduction or interruption to manage anemia. ClinicalTrials.gov ID NCT02207088
Glecaprevir and Pibrentasvir for 12 Weeks for Hepatitis C Virus Genotype 1 Infection and Prior Direct-Acting Antiviral Treatment
ABJM theory as a Fermi gas
The partition function on the three-sphere of many supersymmetric
Chern-Simons-matter theories reduces, by localization, to a matrix model. We
develop a new method to study these models in the M-theory limit, but at all
orders in the 1/N expansion. The method is based on reformulating the matrix
model as the partition function of an ideal Fermi gas with a non-trivial,
one-particle quantum Hamiltonian. This new approach leads to a completely
elementary derivation of the N^{3/2} behavior for ABJM theory and N=3 quiver
Chern-Simons-matter theories. In addition, the full series of 1/N corrections
to the original matrix integral can be simply determined by a next-to-leading
calculation in the WKB or semiclassical expansion of the quantum gas, and we
show that, for several quiver Chern-Simons-matter theories, it is given by an
Airy function. This generalizes a recent result of Fuji, Hirano and Moriyama
for ABJM theory. It turns out that the semiclassical expansion of the Fermi gas
corresponds to a strong coupling expansion in type IIA theory, and it is dual
to the genus expansion. This allows us to calculate explicitly non-perturbative
effects due to D2-brane instantons in the AdS background.Comment: 52 pages, 11 figures. v3: references, corrections and clarifications
added, plus a footnote on the relation to the recent work by Hanada et a
- …